<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222350</url>
  </required_header>
  <id_info>
    <org_study_id>DS8500-A-J201</org_study_id>
    <nct_id>NCT02222350</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase 2, Placebo-controlled, Double-blind Study of DS-8500a in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of DS-8500a compared with
      placebo in Japanese patients with Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of DS-8500a 10 mg and 75
      mg administered orally, once daily, for 28 days, compared with placebo, in Japanese patients
      with Type 2 Diabetes Mellitus in a double-blind, placebo-controlled parallel-group design.
      The primary endpoint is the change in 24-hour weighted mean glucose at day 28 from baseline.
      The safety, pharmacokinetics, and pharmacodynamics of DS-8500a will be evaluated as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in 24-hour weighted mean blood glucose</measure>
    <time_frame>Day -1 (baseline) to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in 24 hour weighted mean blood glucose</measure>
    <time_frame>Day -1 (baseline) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood fasting plasma glucose level</measure>
    <time_frame>Day -1 (baseline) to Days 7, 14, 21, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood plasma glucose level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in the parameter at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood insulin level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in the parameter at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood C-peptide level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in the parameter at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood active GLP-1 level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in the parameter at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood PYY level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in the parameter at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood HbA1c level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in the parameter at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood glycoalbumin level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in the parameter at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events as a measure of safety</measure>
    <time_frame>Day -1 (baseline) to Day 28</time_frame>
    <description>Number of subjects experiencing adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic profile of DS-8500a</measure>
    <time_frame>Day -1 (baseline) to Day 28</time_frame>
    <description>Pharmacokinetic profile of DS-8500a in Japanese subjects with type 2 diabetes mellitus. i.e. Tmax, Cmax, AUC, t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in postprandial plasma glucose level</measure>
    <time_frame>Day -1 (baseline) to Days 14 and 28</time_frame>
    <description>Change in postprandial plasma glucose level (2 hours after a meal) at Day 14 or 28 from Day －1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DS-8500a 10mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg DS-8500a tablet given orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS8500a 75 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg DS-8500a tablet given orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo to match DS-8500a tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo matching DS-8500a tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10mg DS-8500a tablet</intervention_name>
    <arm_group_label>DS-8500a 10mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75mg DS-8500a tablet</intervention_name>
    <arm_group_label>DS8500a 75 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo to match DS-8500a tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 20 years at the time of informed consent

          -  Japanese patients with type 2 diabetes

          -  Patients who have HbA1c ≥ 7.0% and &lt; 10.0% if untreated with antidiabetic agent.

          -  Patients who have HbA1c ≥ 6.5% and &lt; 9.5% if treated with antidiabetic agent.

        Exclusion Criteria:

          -  Patients aged ≥ 70 years at the time of informed consent

          -  Patients with a history of type 1 diabetes or diabetic ketoacidosis

          -  Patients receiving or requiring treatment with insulin

          -  Patients with a body mass index (BMI) of &lt; 18.5 kg/m2 or ≥ 35.0 kg/m2

          -  Patients with an estimated glomerular filtration rate (eGFR), &lt; 45 mL/min per 1.73 m2

          -  Patients with fasting plasma glucose ≥ 240 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Heishinkai Medical Group Incorporated OCROM Clinic</name>
      <address>
        <city>Kasuga</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

